Abbott says payoff from Mylan deal surges, as Mylan shares leap
April 22, 2015 at 10:53 AM EDT
April 22 (Reuters) - Abbott Laboratories on Wednesday said its initial $5.3 billion gain from the recent sale to Mylan of its generic drugs business in developed markets outside the United States has jumped to more than $7 billion, thanks to appreciation of Mylan shares it obtained in the deal.